ArticleActa pharmacologica Sinica2022
New monoamine antidepressant, hypidone hydrochloride (YL-0919), enhances the excitability of medial prefrontal cortex in mice via a neural disinhibition mechanism.
Article in Acta pharmacologica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Cannabidiol Attenuates Methamphetamine-Induced Autophagy in Primary Rat Neurons via the 5-HT1A/AC/cAMP/PKA/CREB Signaling Pathway.International journal of molecular sciences · 2026Article
- Sigma-1R-CD36 axis in myeloid cells contributes to the alleviation of depression-like behaviors.Journal of translational medicine · 2026Article
- Modulation of neuroimmune cytokine networks by antidepressants: implications in mood regulation.Translational psychiatry · 2025Review
- The DRN-VLO pathway via distinct 5-HT synaptic mechanisms modulates neuropathic pain-induced depressive-like behaviors in mice.The journal of headache and pain · 2025Article
- Androgens alleviate the depression-like phenotype in female mice by inhibiting AVPR1a in the hippocampal brain region.Molecular medicine (Cambridge, Mass.) · 2025Article
- Hypidone Hydrochloride (YL-0919), a Sigma-1 Receptor Agonist, Improves Attention by Increasing BDNF in mPFC.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Sex-specific and developmental effects of early life adversity on stress reactivity are rescued by postnatal knockdown of 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Potential common targets of music therapy intervention in neuropsychiatric disorders: the prefrontal cortex-hippocampus -amygdala circuit (a review).Frontiers in human neuroscience · 2025Review
- The role of 5-HTergic neuron activation in the rapid antidepressant-like effects of hypidone hydrochloride (YL-0919) in mice.Frontiers in pharmacology · 2024Article
- The development and benefits of metformin in various diseases.Frontiers of medicine · 2023Review
- Essential role of microglia in the fast antidepressant action of ketamine and hypidone hydrochloride (YL-0919).Frontiers in pharmacology · 2023Article
- Astrocytes underlie a faster-onset antidepressant effect of hypidone hydrochloride (YL-0919).Frontiers in pharmacology · 2023Article
- Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypidone hydrochloride (YL-0919) is a novel antidepressant in clinical phase II trial. Previous studies show that YL-0919 is a selective 5-HT (serotonin) reuptake inhibitor, 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.